AU2022277697A1 - Sars-cov-2 polypeptides - Google Patents

Sars-cov-2 polypeptides Download PDF

Info

Publication number
AU2022277697A1
AU2022277697A1 AU2022277697A AU2022277697A AU2022277697A1 AU 2022277697 A1 AU2022277697 A1 AU 2022277697A1 AU 2022277697 A AU2022277697 A AU 2022277697A AU 2022277697 A AU2022277697 A AU 2022277697A AU 2022277697 A1 AU2022277697 A1 AU 2022277697A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
set forth
acid sequence
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022277697A
Other languages
English (en)
Inventor
Richard B. Kennedy
Inna G. Ovsyannikova
Gregory A. Poland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of AU2022277697A1 publication Critical patent/AU2022277697A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022277697A 2021-05-20 2022-05-19 Sars-cov-2 polypeptides Abandoned AU2022277697A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163190964P 2021-05-20 2021-05-20
US63/190,964 2021-05-20
US202263341771P 2022-05-13 2022-05-13
US63/341,771 2022-05-13
PCT/US2022/030068 WO2022246084A1 (en) 2021-05-20 2022-05-19 Sars-cov-2 polypeptides

Publications (1)

Publication Number Publication Date
AU2022277697A1 true AU2022277697A1 (en) 2024-01-04

Family

ID=82321637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022277697A Abandoned AU2022277697A1 (en) 2021-05-20 2022-05-19 Sars-cov-2 polypeptides

Country Status (10)

Country Link
US (1) US12653880B2 (enExample)
EP (1) EP4294440A1 (enExample)
JP (1) JP2024521098A (enExample)
KR (1) KR20240012394A (enExample)
AU (1) AU2022277697A1 (enExample)
BR (1) BR112023024034A2 (enExample)
CA (1) CA3212678A1 (enExample)
IL (1) IL308465A (enExample)
MX (1) MX2023013665A (enExample)
WO (1) WO2022246084A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4547258A4 (en) * 2022-06-28 2026-08-05 Transcode Therapeutics Inc Matrix-Directed Rig-I Agonitor Nanoparticles and Precursor Compositions and Their Uses in Cancer Therapy
CN115947801B (zh) * 2022-12-29 2026-02-06 中国疾病预防控制中心病毒病预防控制所 一种流感病毒通用和冠状病毒联合多肽及其疫苗的应用
CN116143908B (zh) * 2023-02-10 2026-07-10 武汉华美生物工程有限公司 一种针对VLPs类型抗原免疫产生高效价抗血清的方法
WO2025231068A1 (en) * 2024-04-30 2025-11-06 The Regents Of The University Of Michigan Compositions and methods for enhancing systemic and mucosal immune responses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013032421A2 (pt) 2011-06-29 2017-01-17 Immunotope Inc método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
WO2015175361A1 (en) 2014-05-13 2015-11-19 Immunotope, Inc. Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development
EA201991377A1 (ru) 2017-01-03 2020-01-21 Эмерджекс Ваксинс Холдинг Лимитед Композиции универсальной вакцины против гриппа
SG11202002044WA (en) 2017-09-21 2020-04-29 Emergex Vaccines Holding Ltd MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
JP2021509400A (ja) 2018-01-06 2021-03-25 イマージェクス ヴァクシンズ ホールディング リミテッドＥｍｅｒｇｅｘ Ｖａｃｃｉｎｅｓ Ｈｏｌｄｉｎｇ Ｌｉｍｉｔｅｄ 複数のフラビウイルスの予防および治療を目的としたｍｈｃクラスｉ関連ペプチド
AU2019244435A1 (en) 2018-03-29 2020-10-15 Emergex Vaccines Holding Limited Vaccine compositions
US20210283237A1 (en) 2018-03-29 2021-09-16 Emergex Vaccines Holding Limited Vaccine compositions
CA3099643A1 (en) 2018-05-18 2019-11-21 Emergex Vaccines Holding Limited Reverse peptide vaccine
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021204179A1 (en) * 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
EP4138876A1 (en) * 2020-04-23 2023-03-01 ISA Pharmaceuticals B.V. Immunization against sars-cov-related diseases
GB202008250D0 (en) 2020-06-02 2020-07-15 Emergex Vaccines Holding Ltd Diagnosis, prevention and treatment of coronavirus infection
GB202011652D0 (en) * 2020-07-28 2020-09-09 Univ Oxford Innovation Ltd Polypeptide panels and uses thereof
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
EP4294435A1 (en) 2021-02-16 2023-12-27 Emergex Vaccines Holding Limited Reverse peptides from coronavirus for immunogenic purposes
US20240269264A1 (en) 2021-06-02 2024-08-15 Emergex Vaccines Holding Limited Human coronavirus 229e derived peptides

Also Published As

Publication number Publication date
WO2022246084A1 (en) 2022-11-24
US12653880B2 (en) 2026-06-16
BR112023024034A2 (pt) 2024-02-06
IL308465A (en) 2024-01-01
MX2023013665A (es) 2024-01-08
JP2024521098A (ja) 2024-05-28
CA3212678A1 (en) 2022-11-24
US20220370601A1 (en) 2022-11-24
KR20240012394A (ko) 2024-01-29
EP4294440A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
Liu et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
US20220370601A1 (en) SARS-CoV-2 POLYPEPTIDES
US11998596B2 (en) Immunogenic compositions and vaccines comprising African swine fever virus peptides and proteins and uses thereof
Saunders et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
US20230075527A1 (en) Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
JP7475366B2 (ja) 慢性炎症およびウイルス感染の診断と治療
Madhukalya et al. Nipah virus: pathogenesis, genome, diagnosis, and treatment
JP2025507227A (ja) 新型コロナウイルスｓ２タンパク質のｈｒ領域に由来する組換え融合タンパク質およびその使用
CN103476788A (zh) 免疫原性屈曲病毒肽
US12064476B2 (en) Zika virus immunogenic compositions
Leifer et al. Modified live marker vaccine candidate CP7_E2alf provides early onset of protection against lethal challenge infection with classical swine fever virus after both intramuscular and oral immunization
CN120282795A (zh) Omicron冠状病毒疫苗构建体及其制备和使用方法
BR112020009157A2 (pt) poliepítopo quimérico, polinucleotídeo, vetor, célula hospedeira e composição imunogênica
Honda-Okubo et al. An Advax-CpG55. 2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge
US20240269266A1 (en) Broad-spectrum multi-antigen pan-coronavirus vaccine
Huang et al. Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV
US11040095B2 (en) Human rhinovirus vaccine
EP4531906A1 (en) Live-attenuated sars-cov-2 vaccine
CN108300705B (zh) 稳定呼吸道合胞病毒融合蛋白的方法
CN117479954A (zh) SARS-CoV-2多肽
CN101921310A (zh) 登革病毒特异性hla-a2限制性表位肽及应用
HK40107928A (en) Sars-cov-2 polypeptides
WO2018146257A1 (en) Hepatitis e virus vaccine
KR20080012449A (ko) 뉴클레오캡시드 또는 스파이크 단백질을 이용한 사스진단방법
Dai et al. Production and characterization of Hantaan virus-like particles from baculovirus expression system

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period